Loading resource…

Javier Ampuero & Manuel Romero-Gomez
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease, significantly impacting global health. The recent approval of new therapies like resmetirom and semaglutide marks a pivotal shift in treatment options. However, determining patient eligibility remains complex, necessitating a combination of fibrosis stage assessment, metabolic factors, and non-invasive tools. This document aims to provide insights into the evolving landscape of MASLD management and the implications for clinical practice.
No account needed